drugset / Trial / NCT05567159
A Study of Donanemab (LY3002813) in Healthy Participants
NaSingle-groupOpen-labelBasic science
Summary
The main purpose of this study is to assess how fast donanemab (LY3002813) gets into the blood stream and how long it takes the body to remove it when administered as single dose in healthy participants. The study will also evaluate the safety and tolerability of donanemab. The study will last up to approximately 22 weeks.
Timeline
- Start
- 2022-10-04
- Primary completion
- 2023-07-14
- Completion
- 2023-07-14
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Donanemab | Monoclonal antibody | 350 mg | Intravenous |
Indications
No indication recorded.